The Role of USP22 in Prostate Cancer Development and Progression

摘要 前列腺癌（PCa）是美国男性癌症相关死亡的第二大原因。 虽然器官局限性疾病是可管理的，但晚期和播散性PCa目前没有持久的治疗方法。 治疗方案。因此，了解从早期阶段过渡到 晚期去势抵抗性PCa（CRPC）是关键。虽然这种转变需要雄激素 受体（AR）活性，AR和其他癌基因功能性增加的机制，甚至 雄激素剥夺疗法（ADT）的初始治疗后，尚未完全表征。 USP 22是一种已知的与佐贺转录激活复合物相关的去泛素化酶，最初是由 被称为“癌症死亡”的基因标记。重要的是，USP 22在PCa中显著上调， 晚期疾病患者，特别适用于PCa患者的不良结局。此外，委员会认为， 肿瘤相关USP 22增加AR水平和活性以及c-MYC功能，部分定义了 肿瘤相关USP 22驱动PCa进展的机制。因此，虽然某些后果 肿瘤相关的USP 22表达已经阐明，其余的下游效应尚未阐明。 彻底定性。在本提案中，我将描述USP 22驱动PCa的方式 发展和进步。具体来说，我将描述由USP 22控制的生化事件， 赋予PCa细胞的增殖和存活，此外，我将定义肿瘤相关基因的作用。 关于体内肿瘤发展和治疗性旁路的USP 22。此外，我将扩大我的野心， 我会继续研究癌症中的转录失调一旦我完成了我的博士前研究。

ABSTRACT Prostate cancer (PCa) is the second leading cause of cancer-related death for men in the United States. While organ-confined disease is manageable, advanced and disseminated PCa currently has no durable treatment options. Thus, understanding the causes and consequences of the transition from early stage to late stage castrate-resistant PCa (CRPC) are critical. While this transition has a requisite for androgen receptor (AR) activity, the mechanisms by which AR and other oncogenes are functionally increased, even after initial treatment with androgen deprivation therapy (ADT) have not been completely characterized. USP22, a known deubiquitinase associated with the SAGA transcriptional activation complex, was originally designated in a “death from cancer” gene signature. Importantly, USP22 is significantly upregulated in PCa patients with late-stage disease, and specifically indicates for poor outcome in PCa patients. Moreover, tumor-associated USP22 increases AR levels and activity as well as the c-MYC function, partially defining the mechanism by which tumor-associated USP22 drives PCa progression. Thus, while certain consequences of tumor-associated USP22 expression have been elucidated, the remaining downstream effects have not been thoroughly characterized. In this proposal, I will delineate the manner by which USP22 drives PCa development and progression. Specifically, I will describe the biochemical events controlled by USP22 that confer proliferation and survival on PCa cells, and furthermore I will define the role of tumor-associated USP22 on tumor development and therapeutic bypass in vivo. Moreover, I will expand on my ambition to continue studying transcriptional deregulation in cancer once I complete my predoctoral research.